Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: guanfacine (Tenex) Clear all
Not yet recruiting Early Phase 1 Interventional

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

NCT07757555
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions
Guanfacine (GFC), Cromolyn Sodium, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Recruiting Phase 2 Interventional

Guanfacine for Alcohol Use Disorder (AUD)

NCT06629259
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Guanfacine Extended Release (XR), Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Stress and Medication Effects on Cocaine Cue Reactivity

NCT00613015
View directory record Official record
Conditions
Cocaine Related Disorders
Interventions
Guanfacine, Modafinil, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 25, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

NCT04066088
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Guanfacine extended release (GXR)
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 25, 2026, 1:35 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 25, 2026, 1:35 AM EDT
Not listed Not applicable Interventional

Prospective, Multicenter, RCT of the Tenex Ultrasound System

NCT06137222
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer
Device · Other
Lead sponsor
Tenex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Mobile, Alabama • St. George, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 25, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional

Guanfacine Extended Release and Mindfulness Skills Therapy

NCT03258476
View directory record Official record
Conditions
Stress Disorder
Interventions
Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
10 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 25, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT01156051
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions
Guanfacine extended-release tablets, Placebo comparator
Drug
Lead sponsor
Children's Specialized Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Hamilton, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 25, 2026, 1:35 AM EDT
Recruiting Not applicable Interventional

Evaluation of TENEX for Greater Trochanteric Pain Syndrome (GTPS)

NCT05710627
View directory record Official record
Conditions
Greater Trochanteric Pain Syndrome
Interventions
TENEX
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders

NCT00025779
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders
Interventions
methylphenidate, guanfacine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2009 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combining Varenicline and Guanfacine for Smoking Cessation

NCT04198116
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Guanfacine ER
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 25, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

NCT00389675
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
85
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

NCT00935493
View directory record Official record
Conditions
Cognitive Aging
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
75 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 25, 2026, 1:35 AM EDT
Not yet recruiting Not applicable Interventional

Ultrasound-Guided Percutaneous Needle Tenotomy (PNT) vs Percutaneous Ultrasonic Needle Tenotomy (PUT) for Gluteal Tendinosis

NCT07540806
View directory record Official record
Conditions
Tendinopathy, Tendinosis, Gluteal Tendinitis
Interventions
Percutaneous needle tenotomy (PNT), Percutaneous ultrasonic tenotomy (PUT, Tenex Device)
Procedure · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT01081145
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 25, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy

NCT04384809
View directory record Official record
Conditions
Lateral Epicondylitis (Tennis Elbow)
Interventions
Leukocyte rich platelet rich plasma, Percutaneous Tenotomy
Biological · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Recruiting Phase 4 Interventional

AWARE: Management of ADHD in Autism Spectrum Disorder

NCT05916339
View directory record Official record
Conditions
ADHD, Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Drug
Lead sponsor
Daniel Coury
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Portland, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Guanfacine for PONV and Pain After Sinus Surgery

NCT02882854
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Pain, Postoperative
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 25, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

NCT01681264
View directory record Official record
Conditions
Chronic Pain
Interventions
Morphine, Guanfacine 1mg, Guanfacine 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 25, 2026, 1:35 AM EDT
Completed Early Phase 1 Interventional

Mindfulness-Based ADHD Treatment for Children: a Feasibility Study

NCT04737512
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness-Based ADHD Treatment for Children, Goal-Standard Medication (Treatment as Usual)
Behavioral · Biological
Lead sponsor
Yale University
Other
Eligibility
7 Years to 13 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 25, 2026, 1:35 AM EDT